Following the success of the inaugural SKIN VACCINATION SUMMIT in October 2011, the follow-up meeting SVS 2013 will again provide the skin vaccination community an opportunity to meet and discuss current developments and technologies in the field.
Recognition of the skin by vaccinologists as an ideal anatomical target has gathered momentum in the past decade. The premise that the dense population of APCs can be targeted, stimulated and loaded with antigens to induce robust immune responses and result in more efficacious vaccines has stimulated many efforts to understand skin physiology, the skin immune system antigen presenting cells, effector responses and modes of immune stimulation and delivery formats. The field is ripe to have broad interchange on relevant related disciplines to focus both research and development efforts on more effective and informative directions. With several products in late stage development and a newly licensed delivery device, a timely multi disciplinary interchange is greatly needed to help set the stage for progress that can lead to capitalizing on the immunopotency of the skin to bring about better human health.
The second SKIN VACCINATION SUMMIT – SVS 2013 will again offer an international forum for researchers, both academic and industrial, plus regulators and skin delivery technologists to meet and discuss the current developments and future direction and technology trends in the dynamic field of skin mediated vaccination.
Scientific Advisory Panel
SVS 2013 Conference Chair: Bruce G. Weniger (Chiang Mai University, Chiang Mai, Thailand) and Greg Glenn (Novavax Inc., Rockville, Maryland, USA)
Mark Kendall (University of Queensland, Australia)
Richard Compans (Emory University, Atlanta, Georgia, USA)
Joke Bouwstra (Leiden/Amsterdam Center for Drug Research, The Netherlands)
Behazine Combadiere (INSERM, Paris, France)
Kristine Hansen (3M Drug Delivery Systems, St. Paul, Minnesota, USA)
Niranjan Y. Sardesai (INOVIO Inc., Blue Bell, Pennsylvania, USA)
Richard R. Stout (Bioject Inc., Tualatin, Oregon, USA)
Mark Tomai (3M Drug Delivery Systems, St. Paul, Minnesota, USA)
Darin Zehrung (PATH, Seattle, Washington, USA)
Yotam Levin (NanoPass Technologies Ltd, Rehovot, Israel)
Nathalie Garcon (GSK Biologicals, Rixensart, Belgium)
David Chen (Pfizer, Kalamazoo, Michigan, USA)
Mark Prausnitz (Georgia Institute of Technology, Atlanta, USA)
Ryan Donnelly (Queen’s University Belfast, Northern Ireland, UK)
Christophe Longuet (Fondation Merieux, Lyon, France)
Philippe Laurent (BD Medical Pharmaceutical Systems, Le Pont de Claix, France)
Terry L. Bowersock (Zoetis, Kalamazoo, Michigan, USA)
Michael Royals (PharmaJet Inc., Golden, Coado, USA)
John Clements (Tulane University, New Orleans, Louisiana, USA)
Derek O’Hagan (Novartis Vaccines & Diagnostics, Cambridge, Massachusetts, USA)
Steve Reed (IDRI, Seattle, Washington, USA)
Geert van den Bossche (UNIVAC LLC, Seattle, Washington, USA)
Marcel B.M. Teunissen (University of Amsterdam, Amsterdam, The Netherlands)
Bobby Singh (Corium International, Menlo Park, California, USA)
Skin Vaccination Summit 2013 Scope
- Layers and cells – considerable new data and debate on the skin APCs, their roles in immunity and there relevance to antigen presentation – Special session on Dendritic Cells.
- Principles of Stratum Corneum Disruption – to immunize one has to access the living skin, so there are many techniques under development to do this – physics and physiology as it related to SC disruption/penetration.
- Techniques for SC Disruption/Penetration: Methods and Madness (microneedles, microprojections, dissolvable needle approaches, ID, Patches - size) – Use , cost and commercialisation.
- Techniques for ID injection – New methods and field experience with novel skin vaccines Dermal delivery of DNA vaccines.
- Skin vaccination – mechanistic interpretations (antigen trafficking across skin) - Reactivity issues (adjuvants and repeated dosing).
- Animals and in vitro models for skin delivery – active field, most everyone working in the field needs to upgrade their approach – toxicology.
- Clinical Evidence for the immunological advantage of skin targeting – Clinical data only, many studies and investigators… ID mainly but several techniques.
- Immunological Rationale for skin targeting – effector results, T cells, humoral and mucosal antibodies -preclinical evidence for the immunological advantage of skin targeting – local reactions.
- Adjuvants for skin targeting – there are many cancer trials using skin and delivery adjuvants to the skin - there are many adjuvants in development to target skin – tox/reactogenicity requirements for skin targeting.
- Public health aspects of skin immunization – improving access to vaccines – stabilization technologies to avoid the cold chain – prospects for self-administered vaccines – issues for mass vaccination.
- Prophylactic vs therapeutic vaccines and skin delivery.
- Size of patches or delivery systems – multivalent versus monovalent vaccine applications and live versus inactivated vaccines.
- Formulation matters · Immune medium (cytokine production by DCs, adipocytes, fibroblasts etc) · Immune suppression of skin constituents · In vitro skin models · Regulatory planning for ID vaccines.